Clinical Trial

Treatment of Peyronie's Disease With Platelet-Rich Plasma

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 13, 2025 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this pilot study is to optimize a planned randomized, double-blind, placebo-controlled clinical trial evaluating the effects of Platelet-Rich Plasma (PRP) intralesional injections in men affected by Peyronie's disease (PD) in the fibrotic phase. The pilot study aims to identify potential challenges in the practical execution of the clinical trial, particularly regarding PRP preparation and the blinding process. Furthermore, it seeks to evaluate the effects of PRP injections.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-01-22; most recent amendment 2025-08-11.
Status change: Recruiting → Active, Not Recruiting 2025-08-05
Status change: Not Yet Recruiting → Recruiting 2025-03-10
Trial Details
NCT Number NCT06789510
Lead Sponsor Herlev Hospital
Conditions Peyronies Disease
Enrollment 10 participants
Start Date 2025-03-10
Primary Completion 2025-10-01 (estimated)
Study Completion 2026-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-13